They may also help to identify mechanisms responsible for lung destruction in COPD, which in turn could identify new treatment targets that bronchodilators – although a mainstay of therapy ...

This study documents that anemia occurs relatively frequently in COPD patients and is related to the presence of inflammation. Anemia is an understudied issue in COPD but may be of great ...

In acute infective exacerbation of chronic bronchitis or chronic obstructive pulmonary disease (COPD), adding erdosteine to standard treatment significantly modified the outcome by improving the ...

COPD comprises several conditions, including chronic bronchitis and emphysema, and can be caused by genetics and irritants like smoke or pollution. The disease affects more than 15 million ...

GSK plc GSK announced that the FDA has accepted its regulatory filing, seeking the approval of a new indication for Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD) treatment for ...

GSK’s Nucala is a monoclonal antibody with a novel mechanism of action that targets ... Currently, the drug is not approved for COPD worldwide. In the past three months, shares of GSK have ...